Free Trial
NASDAQ:STRO

Sutro Biopharma (STRO) Stock Price, News & Analysis

Sutro Biopharma logo
$2.51 -0.02 (-0.79%)
(As of 11/22/2024 ET)

About Sutro Biopharma Stock (NASDAQ:STRO)

Key Stats

Today's Range
$2.45
$2.60
50-Day Range
$2.53
$4.50
52-Week Range
$2.13
$6.13
Volume
843,693 shs
Average Volume
834,962 shs
Market Capitalization
$206.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.14
Consensus Rating
Buy

Company Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
88th Percentile Overall Score

STRO MarketRank™: 

Sutro Biopharma scored higher than 88% of companies evaluated by MarketBeat, and ranked 140th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sutro Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sutro Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.92) to ($2.96) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sutro Biopharma is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sutro Biopharma is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sutro Biopharma has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.91% of the outstanding shares of Sutro Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Sutro Biopharma has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Sutro Biopharma has recently decreased by 16.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sutro Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sutro Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.91% of the outstanding shares of Sutro Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Sutro Biopharma has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Sutro Biopharma has recently decreased by 16.08%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sutro Biopharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Sutro Biopharma is held by insiders.

  • Percentage Held by Institutions

    96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sutro Biopharma's insider trading history.
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

HC Wainwright Raises Earnings Estimates for Sutro Biopharma
Analysts Issue Forecasts for Sutro Biopharma FY2024 Earnings
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Sutro Biopharma (STRO) Receives a Buy from Truist Financial
See More Headlines

STRO Stock Analysis - Frequently Asked Questions

Sutro Biopharma's stock was trading at $4.29 at the beginning of the year. Since then, STRO shares have decreased by 41.5% and is now trading at $2.51.
View the best growth stocks for 2024 here
.

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its earnings results on Tuesday, August, 13th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.20. The firm earned $25.71 million during the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative net margin of 77.01% and a negative trailing twelve-month return on equity of 101.89%.

Sutro Biopharma (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Top institutional investors of Sutro Biopharma include Suvretta Capital Management LLC (8.77%), Point72 Asset Management L.P. (3.66%), Geode Capital Management LLC (2.27%) and Parkman Healthcare Partners LLC (2.09%). Insiders that own company stock include Nicki Vasquez, William J Newell and Brunilda Shtylla.
View institutional ownership trends
.

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD).

Company Calendar

Last Earnings
8/13/2024
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.14
High Stock Price Target
$17.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+383.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-106,790,000.00
Pretax Margin
-67.18%

Debt

Sales & Book Value

Annual Sales
$160.96 million
Book Value
$1.35 per share

Miscellaneous

Free Float
77,594,000
Market Cap
$206.97 million
Optionable
Optionable
Beta
1.17
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:STRO) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners